
    
      Participants will be enrolled in 1 of 2 groups. Approximately 120 participants will receive
      0.05, 0.3, or 0.9 mg of ZGN-1061 or placebo (Group 1). An additional 40 participants will
      receive 0.9 or 1.8 mg of ZGN-1061 or placebo (Group 2).
    
  